Literature DB >> 12372402

Delivery of nucleic acid into mammalian cells by anthrax toxin.

Reetika Gaur1, Pradeep K Gupta, Anita Goyal, Winfried Wels, Yogendra Singh.   

Abstract

Gene delivery vehicles based on receptor-mediated endocytosis offer an attractive long-term solution as they might overcome the limitations of toxicity and cargo capacity inherent to many viral gene delivery systems. The protective antigen component of anthrax toxin bind to specific receptors and deliver lethal factor or edema factor into the cytosol of mammalian cells. The N-terminal 254 amino acids of LF (LF(1-254)) binds to PA and, when fused to heterologous proteins, delivers such proteins into the cytosol. However, so far no attempt has been made to use the anthrax toxin system for the intracellular delivery of DNA. In the present study, LF(1-254) of anthrax toxin was fused to the DNA-binding domain of GAL4 protein. The fusion protein (LF(254)-GAL4DBD) showed both PA binding as well as DNA-binding activity in solution. The complex of fusion protein with plasmid DNA containing a reporter gene (luciferase or green fluorescent protein) along with PA delivered plasmid DNA into the cytosol of COS-1 cells. These results suggest that anthrax toxin components can be used as a non-viral system for the efficient delivery of DNA into the cytosol of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372402     DOI: 10.1016/s0006-291x(02)02299-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

Review 1.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

Review 2.  "Alternative" endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery?

Authors:  L K Medina-Kauwe
Journal:  Adv Drug Deliv Rev       Date:  2007-07-05       Impact factor: 15.470

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.